- Home
- TSHA vs BOE Comparison
TSHA vs BOE Comparison
Compare TSHA & BOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- BOE
- Stock Information
- Founded
- TSHA 2019
- BOE 2005
- Country
- TSHA United States
- BOE United States
- Employees
- TSHA N/A
- BOE N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- BOE Trusts Except Educational Religious and Charitable
- Sector
- TSHA Health Care
- BOE Finance
- Exchange
- TSHA Nasdaq
- BOE Nasdaq
- Market Cap
- TSHA 728.4M
- BOE 634.0M
- IPO Year
- TSHA 2020
- BOE N/A
- Fundamental
- Price
- TSHA $2.32
- BOE $11.42
- Analyst Decision
- TSHA Strong Buy
- BOE
- Analyst Count
- TSHA 5
- BOE 0
- Target Price
- TSHA $8.20
- BOE N/A
- AVG Volume (30 Days)
- TSHA 3.7M
- BOE 166.1K
- Earning Date
- TSHA 08-11-2025
- BOE 01-01-0001
- Dividend Yield
- TSHA N/A
- BOE 7.30%
- EPS Growth
- TSHA N/A
- BOE N/A
- EPS
- TSHA N/A
- BOE N/A
- Revenue
- TSHA $7,224,000.00
- BOE N/A
- Revenue This Year
- TSHA N/A
- BOE N/A
- Revenue Next Year
- TSHA N/A
- BOE N/A
- P/E Ratio
- TSHA N/A
- BOE N/A
- Revenue Growth
- TSHA N/A
- BOE N/A
- 52 Week Low
- TSHA $1.05
- BOE $8.80
- 52 Week High
- TSHA $3.31
- BOE $10.48
- Technical
- Relative Strength Index (RSI)
- TSHA 41.03
- BOE 64.66
- Support Level
- TSHA $2.29
- BOE $11.12
- Resistance Level
- TSHA $2.48
- BOE $11.29
- Average True Range (ATR)
- TSHA 0.17
- BOE 0.08
- MACD
- TSHA -0.05
- BOE 0.01
- Stochastic Oscillator
- TSHA 9.21
- BOE 98.72
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About BOE Blackrock Enhanced Global Dividend Trust of Beneficial Interest
Blackrock Enhanced Global Dividend Trust has an investment objective to provide current income and current gains, with a secondary investment objective of long-term capital appreciation. Further, it focuses on investing in a portfolio of equity securities and utilizing an option writing to seek total return performance and enhance distributions.